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Abstract
Gastric marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) lymphoma accounts for 40–50% of
primary gastric lymphomas. Helicobacter pylori infection plays an important role in the pathogenesis. The phenotype of
MALT lymphoma is variable, and lesions may appear as ulcers, nodules, thickening of folds, or erosions. This article is part
of an expert video encyclopedia.
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Materials
• Endoscope: Fujinon EG530FP; Fujinon Europe, Willich,
Germany.
• Electronic endoscopy system: Fujinon Fujiﬁlm Europe
GmbH, Willich, Germany.
Background and Endoscopic Procedure
Gastric marginal zone lymphoma of mucosa-associated
lymphoid tissue (MALT) lymphoma accounts for 40–50% of
primary gastric lymphomas, 20–40% of extranodal lymph-
omas, 4–9% of all malignant lymphomas, and 1–6% of all
gastric malignancies, remaining a rare disease.1,2 However,
incidence is rising, with a noted peak in the seventh decade
and a male:female ratio of approximately 1.5:1.3 Helicobacter
pylori infection plays a major role in the pathogenesis of MALT
lymphoma, leading to a complete remission after eradication
therapy in 50–90% of cases.4,5 It has been widely accepted that
chronic H. pylori infection provides the antigen stimulus,
leading to the clonal expansion of lymphoid cells, resulting in
the evolution of MALT lymphoma. There are no particular
symptoms that point toward this diagnosis; sometimes, for
example, dyspeptic symptoms such as epigastric pain or dis-
comfort located in the upper abdomen may occur. A biopsy is
performed for accurate diagnosis. At endoscopy, this lymph-
oma may appear in a variety of patterns such as erosions,
small nodules, thickening of gastric folds, erythema of the
gastric mucosa, or as an ulcer, etc.6,7 Low-grade lymphomas
often present as ‘normal’-appearing mucosa (20% vs. 0%;
p¼ .0004) or petechial hemorrhage in the fundus (9% vs. 0%;
p¼ .02) more frequently than high-grade lymphomas, being
also more often conﬁned to the antrum (47% vs. 27%, p¼ .03)
and associated with H. pylori infection (88% vs. 52%,
po.0001). On the contrary, high-grade lymphomas present
more commonly as ulcerative (70% vs. 52%; p¼ .03), being
also more frequently diagnosed in stage 4I when compared
with low-grade lymphomas (70% vs. 21%, po.0001).8
Histopathological characteristics are lymphoepithelial le-
sions with glandular invasion by neoplastic centrocyte-like cells
or small lymphoid cells with irregular nuclear contour, nuclear
clefting, hyperchromasia, and with scant to fair amounts of
cytoplasm. Occasional atypical plasmacytoid tumor cells have
been observed. The response to H. pylori eradication therapy is
predicted by stage. Although disease is limited to gastric mucosa
or submucosa, complete remission has been achieved in almost
all patients. If muscularis propria or serosa was already in-
volved, response rates signiﬁcantly dropped. Almost 10% of
gastric MALT lymphomas with t(11;18)(q21;q21) translocation
are resistant to H. pylori antibiotic therapy, indicating a strict
follow-up and, if needed, enhanced therapeutic options, for
example, chemotherapy, immunotherapy (e.g., Rituximab),
and/or radiotherapy for localized disease. There is evidence that
medical therapy is superior to surgery.
Once diagnosis of MALT lymphoma has been made and
H. pylori eradication therapy has been performed, treatment
failure has to be assessed. Although the majority of patients will
respond to medical therapy, timing of rebiopsy is pivotal to
avoid an inappropriate judgment of response failure. Usually
complete resolution takes from several months up to 2 years. It
is recommended to rebiopsy at least 8–12 weeks between ini-
tiation of therapy and follow-up biopsy for MALT lymphomas.
Key Learning Points/Tips and Tricks
• Low-grade lymphomas often present as ‘normal’-appearing
mucosa or petechial hemorrhage in the fundus more
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frequently compared to high-grade lymphomas, being also
more often conﬁned to the antrum and associated with H.
pylori infection. In contrast, high-grade lymphomas present
more commonly as ulcerative, being also more frequently
diagnosed in stage 4I when compared with low-grade
lymphomas.
• Petechial hemorrhage pattern in the fundus may be the
only endoscopic ﬁnding of a MALT lymphoma. In par-
ticular, in patients not currently taking non-steroidal anti-
inﬂammatory drug, adequate tissue samples should be
obtained.
• Before taking biopsies, wash the target lesion with suf-
ﬁcient water with dimethicone to remove mucus.
• Gentle suction should be used when it is difﬁcult to ap-
proach the target lesion.
Scripted Voiceover
Time
(min:sec)
Voiceover text
00:01 This is a gastroscopy in a 58-year-old female patient. In
the retroverted position, a single exophytic, polypoid
mass covered with ﬁbrin can be seen. The lesion is
surrounded by normal looking mucosa. At the fundus
there is another isolated lesion with an ulcerated surface
surrounded by normal looking mucosa. Both lesions do
not have the typical morphology of gastric
adenocarcinoma.
00:32 Indeed biopsy sampling from the lesions revealed a
gastric MALT lymphoma.
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